PROCEPT BioRobotics Corporation (PRCT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 8, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PRCT SEC filings page.
PROCEPT BioRobotics Corporation (PRCT) reported $337.3M in revenue over the twelve months to Jun 30, 2026, up 22.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue growth is improving gross economics and cash consumption, but operating expenses still keep the business materially below break-even.
From FY2023 to FY2025, gross margin expanded from52.2% to63.7% , showing that each sale carried more gross profit. Yet operating margin remained-33.7% in FY2025, indicating that overhead growth still absorbed the product-level improvement.
Revenue reached
The balance sheet is less debt-dependent than the operating losses imply: debt-to-equity was 0.1x and the current ratio was 6.8x in FY2025. Reported liquidity equaled 70.2 months of the latest annual operating outflow, while liabilities of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of PROCEPT BioRobotics Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
PROCEPT BioRobotics Corporation has an operating margin of -33.7%, meaning the company loses $34 on every $100 of revenue. This results in a profitability score of 20/100. This is up from -43.0% the prior year.
PROCEPT BioRobotics Corporation's revenue surged 37.2% year-over-year to $308.1M, reflecting rapid business expansion. This strong growth earns a score of 95/100.
PROCEPT BioRobotics Corporation carries a low D/E ratio of 0.14, meaning only $0.14 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.85, PROCEPT BioRobotics Corporation holds $6.85 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 95/100.
PROCEPT BioRobotics Corporation's operations used $49.0M of cash, and capex of $9.4M added to the outflow, for a free cash flow shortfall of $58.3M. This results in a cash flow score of 6/100.
PROCEPT BioRobotics Corporation's ROE of 0.0% shows moderate profitability relative to equity, earning a score of 31/100. This is unchanged from the prior year.
PROCEPT BioRobotics Corporation scores 3.37, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.0B) relative to total liabilities ($142.2M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
PROCEPT BioRobotics Corporation passes 2 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
PROCEPT BioRobotics Corporation reported a net loss of $96K while operations used $49.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
PROCEPT BioRobotics Corporation reported an operating loss of $103.9M against $3.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
PROCEPT BioRobotics Corporation generated $94.5M in revenue in Q2 2026. This represents an increase of 19.3% from the same quarter a year earlier. Against the prior quarter it is up 13.7%.
PROCEPT BioRobotics Corporation's EBITDA was -$25.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 23.3% from the same quarter a year earlier. Against the prior quarter it is up 17.7%.
PROCEPT BioRobotics Corporation reported -$26.9M in net income in Q2 2026. This represents a decrease of 37.2% from the same quarter a year earlier. Against the prior quarter it is up 15.1%.
PROCEPT BioRobotics Corporation earned -$0.47 per diluted share (EPS) in Q2 2026. This represents a decrease of 34.3% from the same quarter a year earlier. Against the prior quarter it is up 16.1%.
Cash & Balance Sheet
PROCEPT BioRobotics Corporation recorded an outflow of $22.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 24.4% from the same quarter a year earlier. Against the prior quarter it is up 45.9%.
PROCEPT BioRobotics Corporation held $227.9M in cash against $51.7M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
PROCEPT BioRobotics Corporation's gross margin was 66.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.
PROCEPT BioRobotics Corporation's operating margin was -29.0% in Q2 2026, reflecting core business profitability. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.2 percentage points.
PROCEPT BioRobotics Corporation's net profit margin was -28.4% in Q2 2026, showing the share of revenue converted to profit. This is down 3.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 9.6 percentage points.
PROCEPT BioRobotics Corporation's ROE was -7.9% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.
Capital Allocation
PROCEPT BioRobotics Corporation invested $20.1M in research and development in Q2 2026. This represents an increase of 14.0% from the same quarter a year earlier. Against the prior quarter it is down 6.4%.
PROCEPT BioRobotics Corporation invested $3.0M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 5.4% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.
Not reported for Q2 2026.
PRCT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $94.5M+19.3% | $83.1M+20.2% | $76.4M+11.9% | $83.3M+42.8% | $79.2M+48.4% | $69.2M+55.3% | $68.2M+56.6% | $58.4M+66.3% |
| Cost of Revenue | $32.1M+17.1% | $29.2M+16.7% | $30.1M+22.4% | $29.3M+36.6% | $27.4M+25.4% | $25.0M+28.2% | $24.6M+10.0% | $21.5M+32.2% |
| Gross Profit | $62.4M+20.5% | $53.9M+22.2% | $46.3M+6.0% | $54.0M+46.3% | $51.7M+64.4% | $44.2M+76.4% | $43.7M+105.5% | $36.9M+95.6% |
| R&D Expenses | $20.1M+14.0% | $21.5M+30.9% | $19.1M+26.5% | $18.2M+9.3% | $17.6M+0.7% | $16.4M+25.4% | $15.1M+3.9% | $16.6M+43.5% |
| SG&A Expenses | $69.7M+23.7% | $65.1M+17.9% | $58.3M+20.7% | $59.0M+38.2% | $56.3M+38.0% | $55.2M+39.4% | $48.3M+33.0% | $42.7M+29.8% |
| Operating Income | -$27.4M-23.4% | -$32.6M-18.8% | -$31.0M-57.5% | -$23.2M-3.4% | -$22.2M+17.3% | -$27.4M+0.8% | -$19.7M+33.3% | -$22.4M+12.4% |
| EBITDA | -$25.4M-23.3% | -$30.9M-18.9% | -$29.3M-60.7% | -$21.6M-2.3% | -$20.6M+19.4% | -$26.0M+1.9% | -$18.3M+35.4% | -$21.1M+14.1% |
| Interest Expense | $842K-5.9% | $818K-6.7% | $895K-7.6% | $919K-19.4% | $895K-13.1% | $877K-16.1% | $969K-13.9% | $1.1M+11.9% |
| Income Tax | $94K-30.9% | -$43K+8.5% | N/A | N/A | $136K | -$47K | N/A | N/A |
| Net Income | -$26.9M-37.2% | -$31.6M-27.9% | $65.6M-9.4% | -$21.4M-2.1% | -$19.6M+23.6% | -$24.7M+4.7% | $72.5M-7.4% | -$21.0M+14.8% |
| EPS (Basic) | -$0.47-34.3% | -$0.56-24.4% | -$0.53-55.9% | -$0.38+5.0% | -$0.35+30.0% | -$0.45+11.8% | -$0.34+37.0% | -$0.40+21.6% |
| EPS (Diluted) | -$0.47-34.3% | -$0.56-24.4% | -$0.53-55.9% | -$0.38+5.0% | -$0.35+30.0% | -$0.45+11.8% | -$0.34+37.0% | -$0.40+21.6% |
| Diluted Shares (Avg) | 57M+2.9% | 57M+2.9% | N/A | 56M+7.1% | 55M+7.4% | 55M+7.7% | N/A | 52M+7.7% |
PRCT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $479.4M-6.6% | $487.1M-6.2% | $508.1M-4.9% | $511.5M+36.7% | $513.1M+37.1% | $519.4M+35.6% | $534.0M+31.9% | $374.1M-11.2% |
| Current Assets | $420.3M-8.2% | $428.0M-8.1% | $450.4M-6.5% | $454.8M+40.8% | $458.1M+42.3% | $465.8M+41.5% | $481.8M+37.4% | $323.0M-12.4% |
| Cash & Equivalents | $227.9M-24.7% | $245.6M-22.3% | $286.5M-14.1% | $294.3M+49.6% | $302.7M+41.4% | $316.2M+40.2% | $333.7M+29.7% | $196.8M-31.5% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $77.1M+15.0% | $77.5M+24.4% | $70.7M+25.9% | $66.7M+31.2% | $67.0M+52.8% | $62.3M+49.8% | $56.2M+41.3% | $50.9M+20.5% |
| Accounts Receivable | $107.6M+33.1% | $96.4M+21.6% | $83.5M0.0% | $84.5M+22.4% | $80.8M+37.2% | $79.3M+41.3% | $83.5M+72.6% | $69.0M+99.4% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $139.3M+9.4% | $139.4M+7.0% | $142.2M+7.9% | $131.3M-1.2% | $127.3M+3.8% | $130.2M+9.6% | $131.8M+6.3% | $132.9M+9.2% |
| Current Liabilities | $64.2M+29.1% | $63.6M+22.2% | $65.8M+23.8% | $53.9M+0.5% | $49.7M+16.1% | $52.1M+34.7% | $53.1M+15.7% | $53.6M+29.7% |
| Non-Current Liabilities | $75.1M-3.2% | $75.8M-3.1% | $76.4M-2.9% | $77.4M-2.4% | $77.5M-2.8% | $78.2M-2.6% | $78.7M+0.8% | $79.3M-1.4% |
| Long-Term Debt | $51.7M+0.4% | $51.7M+0.3% | $51.6M+0.3% | $51.6M+0.2% | $51.5M+0.2% | $51.5M+0.2% | $51.5M+0.3% | $51.4M+0.3% |
| Total Equity | $340.1M-11.9% | $347.7M-10.7% | $365.9M-9.0% | $380.3M+57.6% | $385.8M+53.2% | $389.2M+47.4% | $402.2M+43.3% | $241.2M-19.4% |
| Retained Earnings | -$700.1M-18.6% | -$673.2M-18.0% | -$641.6M-17.5% | -$611.7M-16.0% | -$590.3M-16.6% | -$570.7M-18.8% | -$546.0M-20.1% | -$527.1M-23.4% |
Not reported in any period shown, so not listed: Goodwill.
PRCT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.3M-28.0% | -$38.1M-124.5% | -$10.3M+68.1% | -$6.6M+64.7% | -$15.0M+4.4% | -$17.0M+47.4% | -$32.4M-30.6% | -$18.8M+0.8% |
| Depreciation & Amortization | $2.0M+25.3% | $1.7M+17.6% | $1.7M+17.6% | $1.6M+21.8% | $1.6M+25.1% | $1.5M+24.6% | $1.5M+10.2% | $1.3M+26.0% |
| Stock-Based Compensation | $14.5M+19.5% | $13.1M+29.3% | N/A | $14.5M+70.2% | $12.2M+52.3% | $10.1M+61.6% | N/A | $8.5M+59.8% |
| Capital Expenditures | $3.0M+5.4% | $2.9M+58.7% | $1.9M+57.6% | $2.9M+1065.9% | $2.8M+168.6% | $1.8M-5.7% | $1.2M-86.5% | $246K-95.7% |
| Free Cash Flow | -$22.2M-24.4% | -$41.0M-118.1% | -$12.2M+63.7% | -$9.5M+50.1% | -$17.8M-6.4% | -$18.8M+45.0% | -$33.6M-0.2% | -$19.0M+23.0% |
| Investing Cash Flow | -$3.0M-5.4% | -$2.9M-58.7% | -$1.9M-57.6% | -$2.9M-1065.9% | -$2.8M-168.6% | -$1.8M+5.7% | -$1.2M+86.5% | -$246K+95.7% |
| Financing Cash Flow | $4.5M+2.7% | $222K-82.9% | $4.4M-97.4% | $1.1M-37.2% | $4.4M-17.3% | $1.3M-49.8% | $170.5M+5850.0% | $1.7M-98.9% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
PRCT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.0%+0.7pp | 64.9%+1.0pp | 60.6%-3.4pp | 64.8%+1.6pp | 65.3%+6.3pp | 63.8%+7.6pp | 64.0%+15.2pp | 63.2%+9.5pp |
| Operating Margin | -29.0%-1.0pp | -39.2%+0.5pp | -40.6%-11.8pp | -27.8%+10.6pp | -28.0%+22.3pp | -39.7%+22.4pp | -28.9%+38.9pp | -38.4%+34.5pp |
| Net Margin | -28.4%-3.7pp | -38.1%-2.3pp | 85.9% | -25.7%+10.2pp | -24.7%+23.3pp | -35.8%+22.5pp | 106.2% | -35.9%+34.2pp |
| Return on Equity | -7.9%-2.8pp | -9.1%-2.7pp | 17.9%-0.1pp | -5.6%+3.1pp | -5.1%+5.1pp | -6.4%+3.5pp | 18.0%-9.9pp | -8.7%-0.5pp |
| Return on Assets | -5.6%-1.8pp | -6.5%-1.7pp | 12.9%-0.6pp | -4.2%+1.4pp | -3.8%+3.0pp | -4.8%+2.0pp | 13.6%-5.8pp | -5.6%+0.2pp |
| Current Ratio | 6.55-2.7x | 6.73-2.2x | 6.85-2.2x | 8.44+2.4x | 9.21+1.7x | 8.95+0.4x | 9.07+1.4x | 6.02-2.9x |
| Debt-to-Equity | 0.150.0x | 0.150.0x | 0.140.0x | 0.14-0.1x | 0.13-0.1x | 0.13-0.1x | 0.13-0.1x | 0.210.0x |
| Asset Turnover | 0.200.0x | 0.170.0x | 0.150.0x | 0.160.0x | 0.150.0x | 0.130.0x | 0.130.0x | 0.16+0.1x |
| FCF Margin | -23.5%-1.0pp | -49.4%-22.2pp | -15.9%+33.3pp | -11.4%+21.2pp | -22.5%+8.9pp | -27.2%+49.6pp | -49.2%+27.7pp | -32.6%+37.8pp |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation PRCT | FY2025 | $308.1M | -$96K | 0.0% | $1.0B | 54/100 |
| Alphatec Holdings, Inc. ATEC | FY2025 | $764.2M | -$143.4M | -18.8% | $1.6B | 35/100 |
| Inspire Medical Systems, Inc. INSP | FY2025 | $912.0M | $145.4M | 16.0% | $2.0B | 64/100 |
| QuidelOrtho Corporation QDEL | FY2025 | $2.7B | -$1.1B | -41.4% | $844.2M | 23/100 |
| Haemonetics Corporation HAE | FY2026 | $1.3B | $97K | 0.0% | $4.6B | 58/100 |
| LivaNova PLC LIVN | FY2025 | $1.4B | -$242.5M | -17.5% | $4.2B | 59/100 |
Where PROCEPT BioRobotics Corporation Ranks
Frequently Asked Questions
What is PROCEPT BioRobotics Corporation's annual revenue?
PROCEPT BioRobotics Corporation (PRCT) reported $308.1M in total revenue for fiscal year 2025. This represents a 37.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is PROCEPT BioRobotics Corporation's revenue growing?
PROCEPT BioRobotics Corporation (PRCT) revenue grew by 37.2% year-over-year, from $224.5M to $308.1M in fiscal year 2025.
Is PROCEPT BioRobotics Corporation profitable?
No, PROCEPT BioRobotics Corporation (PRCT) reported a net income of -$96K in fiscal year 2025, with a net profit margin of 0.0%.
What is PROCEPT BioRobotics Corporation's EBITDA?
PROCEPT BioRobotics Corporation (PRCT) had EBITDA of -$97.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does PROCEPT BioRobotics Corporation have?
As of fiscal year 2025, PROCEPT BioRobotics Corporation (PRCT) had $286.5M in cash and equivalents against $51.6M in long-term debt.
What is PROCEPT BioRobotics Corporation's gross margin?
PROCEPT BioRobotics Corporation (PRCT) had a gross margin of 63.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is PROCEPT BioRobotics Corporation's operating margin?
PROCEPT BioRobotics Corporation (PRCT) had an operating margin of -33.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is PROCEPT BioRobotics Corporation's net profit margin?
PROCEPT BioRobotics Corporation (PRCT) had a net profit margin of 0.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is PROCEPT BioRobotics Corporation's return on equity (ROE)?
PROCEPT BioRobotics Corporation (PRCT) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is PROCEPT BioRobotics Corporation's free cash flow?
PROCEPT BioRobotics Corporation (PRCT) recorded an outflow of $58.3M in free cash flow during fiscal year 2025. This represents a 43.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is PROCEPT BioRobotics Corporation's operating cash flow?
PROCEPT BioRobotics Corporation (PRCT) recorded an outflow of $49.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are PROCEPT BioRobotics Corporation's total assets?
PROCEPT BioRobotics Corporation (PRCT) had $508.1M in total assets as of fiscal year 2025, including both current and long-term assets.
What are PROCEPT BioRobotics Corporation's capital expenditures?
PROCEPT BioRobotics Corporation (PRCT) invested $9.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does PROCEPT BioRobotics Corporation spend on research and development?
PROCEPT BioRobotics Corporation (PRCT) invested $71.3M in research and development during fiscal year 2025.
What is PROCEPT BioRobotics Corporation's current ratio?
PROCEPT BioRobotics Corporation (PRCT) had a current ratio of 6.85 as of fiscal year 2025, which is generally considered healthy.
What is PROCEPT BioRobotics Corporation's debt-to-equity ratio?
PROCEPT BioRobotics Corporation (PRCT) had a debt-to-equity ratio of 0.14 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is PROCEPT BioRobotics Corporation's return on assets (ROA)?
PROCEPT BioRobotics Corporation (PRCT) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is PROCEPT BioRobotics Corporation's P/E ratio?
PROCEPT BioRobotics Corporation (PRCT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $1.0B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is PROCEPT BioRobotics Corporation's price-to-sales ratio?
PROCEPT BioRobotics Corporation (PRCT) trades at 3.0x sales, its market capitalization divided by revenue of $337.3M revenue, trailing 12 months to June 30, 2026. The market capitalization is $1.0B as of Oct 8, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does PROCEPT BioRobotics Corporation's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, PROCEPT BioRobotics Corporation (PRCT) held $286.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $49.0M over that year. Dividing the one by the other, the reported balance equals about 70 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is PROCEPT BioRobotics Corporation's Altman Z-Score?
PROCEPT BioRobotics Corporation (PRCT) has an Altman Z-Score of 3.37, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is PROCEPT BioRobotics Corporation's Piotroski F-Score?
PROCEPT BioRobotics Corporation (PRCT) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are PROCEPT BioRobotics Corporation's earnings high quality?
PROCEPT BioRobotics Corporation (PRCT) reported a net loss of $96K while operations used $49.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can PROCEPT BioRobotics Corporation cover its interest payments?
PROCEPT BioRobotics Corporation (PRCT) reported an operating loss of $103.9M against $3.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is PROCEPT BioRobotics Corporation?
PROCEPT BioRobotics Corporation (PRCT) scores 54 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.